Yasufumi Masaki
Kanazawa Medical University
SurgeryPathologyOncologyHematologyImmunologyBiopsyAnasarcaChemotherapyPrednisoloneOrganomegalyDiffuse large B-cell lymphomaDiseaseLymphomaBone marrowIntravascular large B-cell lymphomaIgG4-related diseaseRituximabMedicineBiologyGastroenterology
Publications 162
#1Hiroshi Kawabata (Kanazawa Medical University)H-Index: 28
#2Shino Fujimoto (Kanazawa Medical University)H-Index: 6
Last. Yasufumi Masaki (Kanazawa Medical University)H-Index: 28
view all 22 authors...
To identify prognostic factors for TAFRO syndrome, a rare inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Data of patients with TAFRO syndrome were extracted from a Japanese patient registry. Patients were divided into groups according to the clinical and laboratory parameters at initial presentation. Cut-off values for the laboratory parameters were determined using receiver operating cha...
#1Kazuyuki Shimada (Nagoya University)H-Index: 63
#2Ken-ichi YoshidaH-Index: 28
Last. Hitoshi Kiyoi (Nagoya University)H-Index: 50
view all 32 authors...
3 CitationsSource
#1Ken Ohmachi (Tokai University)H-Index: 12
#2Tomohiro KinoshitaH-Index: 42
Last. Hirokazu NagaiH-Index: 16
view all 33 authors...
Abstract Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (RW-CHOP) in patients with untreated DLBCL, we conducted a phase 2/3 study (JCOG0601, jRCTs031180139). Patients were randomly assigned to R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 ...
1 CitationsSource
#1Katsuhiro MiuraH-Index: 10
#2Hideki TsujimuraH-Index: 11
Last. Masatoshi KannoH-Index: 6
view all 21 authors...
#1Shino Fujimoto (Kanazawa Medical University)H-Index: 6
#2Hiroshi Kawabata (Kanazawa Medical University)H-Index: 28
Last. Yasufumi Masaki (Kanazawa Medical University)H-Index: 28
view all 13 authors...
TAFRO syndrome is a systemic inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Mortality in patients with this syndrome is high; however, an optimal treatment strategy has not been established. To explore the strategy, we retrospectively analyzed 81 patients with TAFRO syndrome registered in the Multicenter Collaborative Retrospective Study for Establishing the Concept of TAFRO Syndrome in J...
1 CitationsSource
#1Kohei Shiroshita (Keio: Keio University)H-Index: 2
#2Taku Kikuchi (Keio: Keio University)H-Index: 7
Last. Shinichiro Okamoto (Keio: Keio University)H-Index: 47
view all 9 authors...
An inguinal lymph node biopsy of a woman with a one-month history of a progressive fever, fatigue, dyspnea, skin rash, and lymphadenopathy revealed a well-preserved basic structure, hyperplastic germinal centers, and an interfollicular region containing polyclonal plasma cell sheets, suggesting plasma cell-type multicentric Castleman disease (MCD). We initiated prednisolone and anti-interleukin (IL)-6 antibody (tocilizumab), without success. A biopsy specimen re-evaluation detected CD20-positive...
#1Hiroto Yanagisawa (Kanazawa Medical University)
#2Shuichi Mizuta (Kanazawa Medical University)H-Index: 12
Last. Yasufumi Masaki (Kanazawa Medical University)H-Index: 28
view all 11 authors...
#1Takuji Nakamura (Kanazawa Medical University)H-Index: 9
#2Tomomi Satoh-Nakamura (Kanazawa Medical University)H-Index: 2
Last. Hisanori Umehara (Kanazawa Medical University)H-Index: 43
view all 28 authors...
AbstractBackground: IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and tissue infiltration by IgG4-positive plasma cells. The pathogenesis of this disease is not clear. Tran...
#1Kazuyuki Shimada (Nagoya University)H-Index: 63
#2Motoko Yamaguchi (Mie University)H-Index: 32
Last. Tomohiro KinoshitaH-Index: 42
view all 34 authors...
Summary Background Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. Methods PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan. Eligible patients ...
10 CitationsSource
#1Yasufumi Masaki (Kanazawa Medical University)H-Index: 28
#2Hiroshi Kawabata (Kanazawa Medical University)H-Index: 28
Last. Sadao Aoki (Niigata University of Pharmacy and Applied Life Sciences)H-Index: 5
view all 10 authors...
15 CitationsSource